Amprenavir 161814-49-9
Amprenavir (Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200mg, delivered in eight very large gel capsules.
| Systematic (IUPAC) name: |
(3S)-oxolan-3-ylN-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate |
| Amprenavir CAS number: |
161814-49-9 |
| ATC code: |
J05AE05 |
| PubChem: |
65016 |
| DrugBank: |
APRD00605 |
| Formula: |
C25H35N3O6S |
| Molecular mass: |
505.628 g/mol |
| Amprenavir Assay/Purity: |
Typically NLT 98% |
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
